Innate Pharma (NASDAQ:IPHA – Get Free Report) had its price target hoisted by equities researchers at BTIG Research from $8.00 to $9.00 in a research note issued on Wednesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. BTIG Research’s price objective would suggest a potential upside of 318.60% from the stock’s previous close.
Other equities research analysts also recently issued reports about the stock. Leerink Partners raised shares of Innate Pharma from a “market perform” rating to an “outperform” rating and set a $4.00 price target for the company in a report on Tuesday. Weiss Ratings upgraded Innate Pharma from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, June 26th. UBS Group reiterated a “buy” rating on shares of Innate Pharma in a research report on Tuesday. Citigroup raised shares of Innate Pharma from a “buy” rating to an “outperform” rating in a research report on Tuesday. Finally, HC Wainwright lifted their price target on shares of Innate Pharma from $5.00 to $7.00 and gave the company a “buy” rating in a research report on Monday. Five equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $6.67.
View Our Latest Research Report on IPHA
Innate Pharma Stock Down 3.2%
Hedge Funds Weigh In On Innate Pharma
Institutional investors have recently modified their holdings of the business. Jane Street Group LLC bought a new stake in shares of Innate Pharma in the fourth quarter worth $162,000. Millennium Management LLC bought a new stake in shares of Innate Pharma during the 4th quarter worth about $36,000. Finally, OLD Mission Capital LLC acquired a new stake in shares of Innate Pharma in the fourth quarter valued at approximately $50,000. Institutional investors own 0.16% of the company’s stock.
Key Innate Pharma News
Here are the key news stories impacting Innate Pharma this week:
- Positive Sentiment: Strategic Sobi partnership: Innate Pharma and Swedish Orphan Biovitrum (Sobi) agreed to advance lacutamab into a pivotal Phase 3 trial for a rare form of T-cell lymphoma. The deal is expected to provide financing and development support for the cancer therapy, reducing some execution and funding risk. Innate Pharma Jumps as Sobi Deal Boosts Secured Financing for Advancing Rare Skin Cancer Therapy
- Positive Sentiment: Analyst upgrade: Leerink Partners raised Innate Pharma from “market perform” to “outperform” and assigned a $4.00 price target, signaling considerable potential upside from recent trading levels.
- Positive Sentiment: Long-term earnings outlook improved: HC Wainwright maintained its “Buy” rating and $7.00 target while raising its FY2028 EPS estimate to $(0.15), FY2029 to $0.23, and FY2030 to $0.58. The revisions imply a path to profitability beginning in FY2029.
- Neutral Sentiment: Short-interest data is not meaningful: Reported short interest remained at zero shares, with a zero-day short-interest ratio. This provides little indication of trading pressure because the reported figures show no meaningful short position.
- Negative Sentiment: Near-term earnings estimates were cut: HC Wainwright lowered its FY2026 EPS forecast to $(0.79) from $(0.65) and FY2027 to $(0.59) from $(0.51). These deeper projected losses may be weighing on the stock despite the improved longer-term outlook.
Innate Pharma Company Profile
Innate Pharma SA is a clinical-stage biotechnology company specializing in the discovery and development of antibody-based therapies that harness the body’s innate immune system to combat cancer. Founded in 1999 and headquartered in Marseille, France, the company pioneers novel monoclonal antibodies designed to activate natural killer cells and macrophages, offering a complementary approach to existing immuno-oncology treatments.
The company’s lead program, monalizumab, targets the NKG2A immune checkpoint receptor and is being developed in collaboration with AstraZeneca.
Read More
- Five stocks we like better than Innate Pharma
- Paramount’s 30-Film Promise Puts AMC Back in the Box Office Conversation
- DraftKings’ Predictions Push Could Be the Bet That Matters Most
- Atlassian Just Pulled Off the Software Comeback Wall Street Wanted
- AST SpaceMobile Earnings Just Reminded Investors How Risky Space Can Be
Receive News & Ratings for Innate Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innate Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
